Abbott Raises Full-Year Guidance Exceeding Expectations
Abbott Laboratories (ABT) increased its full-year guidance above market expectations following a better-than-expected Q2 2026 performance, leading to a ~3% rise in premarket trading. The company revised upwardly for adjusted earnings.
Tickers: $ABT
Topics: Earnings Outlooks Stock Movement